Plenary speakers

Peter Carmeliet

Leuven, Belgium

Monday 27 May METABOLIC DYSFUNCTION IN CARDIOVASCULAR DISEASE

Angiogenesis Revisited: Role and (Therapeutic) Implications of Endothelial Metabolism

Peter Carmeliet is Professor at the Katholieke Universiteit Leuven and Adjunct Director of the VIB Vesalius Research Center, KU Leuven, Belgium. He is internationally renowned for his research on the growth and functioning of blood vessels, with key findings including identification of which signalling molecules play a role in the formation of new blood vessels, as well as investigation of vascular growth in tumours. His research interests also include investigating the molecular basis of endothelial cell dysfunction and regeneration. Professor Carmeliet was awarded the 2018 Heineken Prize for Medicine for his pioneering research on blood vessel formation, elected a foreign member of the Royal Netherlands Academy of Arts and Sciences in 2017, and the recipient of the 2016 Anitschkow Award from the European Atherosclerosis Society.

M. John Chapman

Paris, France

Wednesday 29 May LOOKING TO THE FUTURE - NOVEL TREATMENT STRATEGIES

The HDL story: time to reconsider?

Lp(a) above and beyond LDL?

Monday 30 November Educational CME accredited programme

Different approaches to LDL lowering: An overview of options including nutrition, food supplements, and drug therapy

Monday 30 November Educational CME accredited programme

Panel discussion: When & how to use nutraceuticals in primary prevention

Monday 30 November Special lectures

Welcome and introduction

Monday 30 November Special lectures

Right diagnosis for non-classical dyslipidemia

Monday 30 November Special lectures

Q&A

M. John Chapman is Research Professor at the University of Pierre and Marie Curie, and Director Emeritus of the National Institute for Health and Medical Research (INSERM), Pitié-Salpétrière University Hospital, Paris, France. Together with Professor Henry Ginsberg (University of Columbia, New York, USA) he has led the EAS Consensus Panel initiative (for full details of the Consensus Panel papers see https://www.eas-society.org/page/consensus_papers ). Professor Chapman undertook his undergraduate studies at Aberdeen University and the Middlesex Hospital Medical School, University of London. He subsequently trained in cardiovascular lipidology at the Cardiovascular Research Institute of the University of California Medical Center, and the Gladstone Foundation for Cardiovascular Disease, San Francisco, USA. He is the recipient of the 2014 European Lipid Science Award and the 2015 Antonio M. Gotto Jr Prize for Atherosclerosis Research from the International Atherosclerosis Society. Present research interests include the relationship of the lipidome and proteome to the functionality of high-density lipoprotein (HDL) particles in health and cardiometabolic disease, and on the development of new anti-atherosclerotic therapeutics targeted to HDL.

Ian Graham

Dublin, Ireland

Tuesday 28 May PREVENTING CVD RISK: WHERE DO WE STAND?

Estimating risk: What's new?

Ian Maklim Graham FRCPI, FESC, FTCD Biographical note Ian Graham is Professor of Cardiovascular Medicine in Trinity College, Dublin, and Professor Emeritus of Preventive Cardiology at the Royal College of Surgeons in Ireland. He is a member of the Board of the European Society of Cardiology, Chairman of the Adelaide Health Foundation and of its Health Policy Initiative. He is a member of the 6th Joint European Societies Task Force on the Prevention of Cardiovascular Disease in clinical practice and of its Prevention Implementation Committee, having Chaired the 4th Task Force. He is co-Chair the 2016 European Guidelines on the management of dyslipidaemias. Prof Graham studied medicine at Trinity College in Dublin, and worked in Dublin and Cambridge before becoming Head of Cardiology at Tallaght Hospital in Dublin and Vice-Chair of its Board of management. He was Director of Research at St Vincent’s Hospital and at the Irish Heart Foundation. He is past President of the Irish Heart Foundation, the Dublin University Biological Association and the Irish Hyperlipidaemia Association. He founded the Irish National Cardiac Surgery register. He is an honorary Fellow of Trinity College in Dublin, and recipient of the Stokes Medal of the Irish Cardiac Society, and the Sir Thomas and Lady Dixon Medal from the Royal Victoria Hospital in Belfast. He held a Medical Research Council Fellowship, a EU travelling Fellowship at Erasmus University in Rotterdam and an ISFC Cardiovascular Epidemiology Fellowship. Prof Graham is Project leader of the EU Concerted Action Project SCORE (Systematic COronary Risk Evaluation) and of its electronic derivative, HeartScore. He is a member of the EuroAspire risk factor audit, and Project Leader of a simplified international audit, SURF (Survey of Risk Factors). Research interests include the natural history of coronary heart disease, cardiovascular risk estimation, homocysteine and vascular disease, health policy and planning and the evaluation of therapies. He has written extensively in these areas. ian@grahams.net

Helen Hobbs

Dallas, USA

Monday 27 May METABOLIC DYSFUNCTION IN CARDIOVASCULAR DISEASE

Lipids, lipases and fatty liver disease

Sunday 26 May Anitschkow Lecture

The Anitschkow Lecture - A journey from plaque to paté

Helen H. Hobbs, M.D., is an Investigator of the Howard Hughes Medical Institute and a Professor of Internal Medicine and Molecular Genetics at the University of Texas Southwestern Medical Center. She holds the Dallas Heart Ball Chair in Cardiology Research, the Philip O’Bryan Montgomery Jr., M.D., Distinguished Chair in Developmental Biology, and the Eugene McDermott Distinguished Chair for the Study of Human Growth and Development. She obtained her undergraduate degree from Stanford University prior to attending Case Western Reserve University School of Medicine.

After completing an internship in internal medicine at Columbia-Presbyterian Medical Center, she moved to Dallas, Texas where she finished her clinical training and served as chief resident in internal medicine at Parkland Memorial Hospital. She worked as a postdoctoral fellow in the laboratory of Drs. Michael Brown and Joseph Goldstein before joining the faculty of UT Southwestern in 1987.

Currently, Professor Hobbs is Director of the McDermott Center for Human Growth and Development, which serves as the Center for Human Genetics at UT Southwestern. She is also Director of the Dallas Heart Study, a longitudinal, multiethnic, population-based study of Dallas County. Her professional affiliations include the Arteriosclerosis, Thrombosis and Vascular Disease Council of the American Heart Association, the Association of American Physicians, the American Society of Human Genetics and the American Society of Clinical Investigation. Professor Hobbs has received numerous awards, most recently the Passano Award (with Jonathan Cohen) in 2016, and the Breakthrough Prize in Life Sciences and Pearl Meister Greengard Prize, Rockefeller University, both in 2015.

 

Thomas Lüscher

Zurich, Switzerland

Tuesday 28 May PREVENTING CVD RISK: WHERE DO WE STAND?

Estimating risk: What's new?

Professor Lüscher studied medicine at the University of Zurich and obtained the board certification in internal medicine and cardiology. He trained in cardiovascular research and in cardiology and specifically in echocardiography at the Mayo Clinic in Rochester, MN, USA and was later Professor of Pharmacotherapy at the University of Basel, then Professor of Cardiology at the University of Berne, before assuming a position as Professor and Chairman of Cardiology and Director of the University Heart Center at the University Hospital Zurich and Director of the Center for Molecular Cardiology at the University of Zurich, Switzerland. He is now Director of Research, Education & Development and Consulting Cardiologist at the Royal Brompton & Harefield Hospital Trust and the Imperial College in London.

Clinical Competence and Activity:

Professor Lüscher is an active general and interventional cardiologist with a broad clini-cal scope and large experience in prevention, coronary and valvular heart disease, percutaneous interventions and heart failure. He has sucessfully taken care of cardiac patients for many years from many countries.

Research:

Professor Lüscher has been a mentor of numerous physicians and scientists from many countires. His research is translational in nature and focuses on coronary artery disease, specifically on the role of endothelium-derived mediators in the regulation of vascular tone and structure, platelet-vessel wall interactions, coagulation in aging, hy-pertension, lipid disorders and atherosclerosis. More recently, inflammatory pathways in coronray artery disease and particularly in acute coronary syndromes has been at the center of his interest. Professor Lüscher has published extensively, authoring or co-authoring over 500 original research articles and more than 200 reviews, book chapters and monographs including the ESC Textbook of Cardiovascular Medicine.

Recognition and Awards:

By the Institute for Scientific Information he has been rated as one of the 0.5% most cited scientists worldwide. He has obtained numerous research prizes and prestigious lecturerships worldwide. He is a member of many editorial boards and was Associate Editor Europe of Circulation (Journal of the American Heart Association) from 2004 to 2008. Since 2009 he is chairman of the publications committee of the European So-ciety of Cardiology (ESC) and an ex-officio member of the ESC board as well as editor-in-chief of the European Heart Journal.

Laszlo Nagy

Florida, USA

Wednesday 29 May LOOKING TO THE FUTURE - NOVEL TREATMENT STRATEGIES

System-level analyses of inflammatory and repair macrophages reveal an integrated circuitry of lipid and epigenomic changes

László Nagy is Professor of Biochemistry and Molecular Biology, University of Debrecen (since 2006), Head of the Center for Clinical Genomics and Personalized Medicine Hungary (since 2000) and Director of Genomic Control of Metabolism Program and Professor of the Diabetes & Obesity, Research Center Sanford Burnham Prebys Medical Discovery Institute at Lake Nona (since 2013). After completing his medical degree and PhD at the University Medical School, Debrecen, Hungary he undertook postdoctoral research at the University of Texas Medical School, Houston, USA (1992 – 1995). Subsequent appointments included International Research Scholar of the Howard Hughes Medical Institute (2001-2011), a Wellcome Trust International Senior Research Fellow (2005-2010), and a Fulbright Scholar Visiting Scientist, The Salk Institute for Biological Studies (2010-2011). His affiliations include the Endocrine Society (USA), American Society of Biochemistry and Molecular Biology, American Association of Immunologists, and the American Physiological Society. He is a founding member of the Hungarian Society for Bioinformatics.  Professor Nagy is the recipient of numerous awards, most recently the ESCI Award for Excellence in Biomedical Investigation (2008), Academia Europaea (2012), Scientist of the Year 2012 (City of Debrecen, Dehir), and the Béla Tankó prize (2014).

 

Matthias Nahrendorf

Boston, USA

Wednesday 29 May LOOKING TO THE FUTURE - NOVEL TREATMENT STRATEGIES

The immune system: The next game-changer?

Matthias Nahrendorf, MD PhD, is a Professor at Harvard Medical School and a Principal Investigator at the MGH Center for Systems Biology. He studies the function, supply and production of leukocytes, and the signals that regulate hematopoiesis after injuries such as myocardial infarction or stroke. He described that after MI, the spleen releases a large population of ready-made leukocytes that travel to the ischemic heart (Science 2009). He further found that MI and chronic stress increases sympathetic nerve activity in the bone marrow. This modulates the hematopoietic stem cell niche, activating migration and proliferation of myeloid progenitor cells (Nature 2012, Nat Med 2014). Resident macrophages, on the other hand, do not derive from circulating cells and promote steady state functions such as cardiac conduction (Cell 2017). The laboratory also develops and employs imaging to sample biology non-invasively, using MR, nuclear, optical and microscopic modalities. Dr. Nahrendorf is an editorial board member of the European Heart Journal, JACC, Circ Res, ATVB, Circulation, Cardiovascular Research and The Journal of Nuclear Medicine. He published >200 peer reviewed articles, was given the MGH Research Scholar Award in 2014, the Basic research Award of the German Society of Cardiology in 2015 and the NHLBI Outstanding Investigator Award in 2018.

Luke A. O’Neill

Dublin, Ireland

Luke O’Neill is Professor of Biochemistry (Inflammation Research) in the School of Biochemistry and Immunology, Trinity Biomedical Sciences Institute, Trinity College Dublin, Ireland. His research aims to provide a molecular understanding of innate immunity and inflammation, specifically the receptors involved in innate immunity, such as Toll-like receptors (TLRs) and Nod-like receptors (NLRs, including Nlrp3), and signals activated. The role played by this system in inflammatory diseases is also under investigation. Ultimately, insights from this research may help in the design of novel treatments and diagnostics that could be applied to a range of diseases including atherosclerosis, sepsis, arthritis and cancer.

Chris Packard

Glasgow, UK

Tuesday 28 May PREVENTING CVD RISK: WHERE DO WE STAND?

Biomarkers predicting CVD

Monday 30 November Educational CME accredited programme

Current evidence for LDL causality; goals and targets

Chris Packard is Professor of Vascular Biochemistry and a Senior Research Fellow at the University of Glasgow. His research has focused on lipoprotein metabolism and how it is affected by diets and drugs, and he has played a key role in large scale clinical trials of lipid lowering agents. More recently, his research interests have extended to the study of emerging risk factors for coronary heart disease, the metabolic consequences of insulin resistance and the causes of the dyslipidaemia in metabolic syndrome, the health consequences of social deprivation, as well as exploration of the mechanism of action of novel lipid lowering drugs. Key contributions from his research include evaluation of the role of the low-density lipoprotein (LDL) receptor in vivo, the discovery of metabolic channelling in the apolipoprotein B lipoprotein delipidation cascade, and the formulation of models to explain the generation of small, dense LDL. Outside the laboratory, Professor Packard is active in local and national initiatives to promote health gains from medical research. He was founding chairman of NEXXUS, the West of Scotland Bioscience Network which promoted community building and knowledge exchange between life sciences industry, academia and the UK National Health Service.

Kausik Ray

London, UK

Tuesday 28 May PREVENTING CVD RISK: WHERE DO WE STAND?

Estimating risk: What's new?

Monday 27 May Workshop session Monday morning

FHSC: What have we learned?

Monday 30 November Late breaking abstracts

PREMATURE MORBIDITY AND MORTALITY AMONG DIAGNOSED AND POTENTIALLY UNDIAGNOSED FAMILIAL HYPERCHOLESTEROLEMIA PATIENTS IN THE GENERAL POPULATION: AN OBSERVATIONAL STUDY OF OVER 1.7 MILLION HEALTH RECORDS

Monday 30 November Breakfast symposia

The latest updates on the Familial Hypercholesterolemia Study Collaboration

Monday 30 November Educational symposia

Lessons from real-world data

Monday 30 November Educational symposia

Very high-risk patients: time for action

Kausik Kumar Ray is currently Professor of Public Heath, Deputy Director of Imperial Clinical Trials Unit and Head of Commercial Trials within the Department of Public Health and Primary Care, School of Public Health, Imperial College London. Professor Ray received his medical education (MB ChB, 1991) at the University of Birmingham Medical School, his MD (2004) at the University of Sheffield, a postdoctoral fellowship at Harvard Medical School and finally an MPhil in epidemiology (2007) from the University of Cambridge. A Fellow of the American College of Cardiology, the European Society of Cardiology, the American Heart Association and the Royal College of Physicians, Kausik Ray is also a member of the British Cardiovascular Society and European Atherosclerosis Society also serving on the EAS Consensus panel. Professor Ray has been the national lead investigator (SC or EC member) for several major medical trials, and is currently involved in 8 ongoing trials in lipids and diabetes and the PI for ORION 1 assessing PCSK9 inhibition through RNA interference and BETONMACE assessing BET protein inhibition in patients with ACS. Professor Ray’s research interests have focused on the prevention of coronary disease with a focus on lipids, diabetes, biomarkers and risk prediction. He has an H index of 59, an i10 of 123 and over 26,000 citations overall, including over 170 publications in journals including NEJM, Lancet, JAMA, Archives of Internal Medicine, Circulation, the Journal of the American College of Cardiology, and the European Heart Journal. Key original contributions which have influenced European and American guidelines include demonstrating the early benefits of statin therapy post ACS, the impact of more/less intensive glycaemic control on CVD and the risks/benefits of aspirin therapy in primary prevention. Recently, his work on statins and diabetes risk led to a global label change for statins by the FDA and EMEA. Currently Professor Ray leads the EAS FH Studies collaboration which is the first global registry of FH and includes 68 countries, as well as being the Senior PI for the TOGETHER study looking at cardiometabolic risk in the vascular health checks in 250,000 people in London.

Paul Ridker

Boston, USA

Tuesday 28 May Keynote Lecture

Inflammation inhibition and atherothrombosis

Paul M Ridker is the Eugene Braunwald Professor of Medicine at the Harvard Medical School and directs the Center for Cardiovascular Disease Prevention, a translational research unit at the Brigham and Women’s Hospital in Boston. He is a graduate of Brown University (1981), the Harvard Medical School (1986), the Harvard School of Public Health (1992), and has received honorary medical degrees from several international institutions. As a preventive cardiologist, Dr. Ridker is best known for his work developing the inflammatory hypothesis of heart disease. His primary research brings together classical tools of large-scale, population-based epidemiology with emerging genetic and molecular techniques designed to improve the ability to predict and prevent vascular disease. Specific areas of interest involve inflammatory mechanisms of heart disease and molecular and genetic determinants of haemostasis, thrombosis, and inflammation with a focus on “predictive medicine”, early disease diagnosis, and the underlying causes and prevention of acute coronary syndromes. Dr Ridker was the Principal Investigator of the Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS) and the NHLBI funded Cardiovascular Inflammation Reduction Trial (CIRT).

Heribert Schunkert

Munich, Germany

Tuesday 28 May PREVENTING CVD RISK: WHERE DO WE STAND?

The genetic burden in CVD

Heribert Schunkert, MD is Professor of Cardiology of the Technische Universitaet Munich, Director of the Cardiology Department and Medical Director of the German Heart Centre Munich. He completed a research fellowship at Brigham and Women,s Hospital, Boston, USA and clinical fellowships at Beth Israel Hospital and at the Universitaetsklinikum, Regensburg and the Massachusetts General Hospital, Boston, USA. From 2002-2012 Prof. Schunkert was Director of Internal Medicine and Cardiology at the University of Luebeck. He conducts research in the molecular genetics of multifactorial cardiovascular disease.He coordinates several EU- and BMBF-sponsored projects as well as the European-American Leducq network CADgenomics to identify the genetic roots of myocardial infarction. He served in the Board of Directors of the German Societies of Hypertension (DHZ) as well as Cardiology (DGK). He is the author of more than 500 publications in international journals.

Douglas R. Seals

Boulder, USA

Monday 27 May METABOLIC DYSFUNCTION IN CARDIOVASCULAR DISEASE

Cardiovascular aging and mitochondia function

Douglas R. Seals is the Distinguished Professor, Department of Integrative Physiology, University of Colorado Boulder. After receiving his PhD in applied exercise physiology, Dr Seals undertook postdoctoral studies at the Washington University School of Medicine, St Louis, and Associate Professorships at the University of Arizona, and University of Colorado Boulder. His recent awards include a National Institute on Aging MERIT Award (2004-current), and the Edward F. Adolph Distinguished Lecturer, American Physiological Society (2013). His research interests include investigation of changes in systolic blood pressure, large artery stiffness and vascular endothelial function that occur with physiological and pathophysiological aging; biological and lifestyle factors that influence cardiovascular aging; integrative (molecular to systemic) mechanisms that mediate cardiovascular aging and its modulation by biological and lifestyle factors; and interventions to improve adverse physiological changes associated with aging, including cardiovascular dysfunction, reductions in motor performance and impairments in cognitive function.

Lale Tokgözoglu

Ankara, Turkey

Dyslipidaemia guidelines: What is new?

Monday 30 November Educational CME accredited programme

Physician-patient relationship: Challenges and opportunities

Monday 30 November Breakfast symposia

Roundtable discussion and Q&A - making sense of the latest data and what it means for high risk patients

S. Lale Tokgözoğlu, M.D., F.A.C.C., F.E.S.C. was born in 1959 in Ankara, Turkey. She graduated from the Hacettepe University Faculty of Medicine in 1982 on the honor roll. After finishing the Internal Medicine Residency program in the Hacettepe University Faculty of Medicine Department of Internal Medicine on 1988, she completed a fellowship program on Cardiology and Atherosclerosis at the Baylor College of Medicine in Houston, Texas. Dr. Tokgözoğlu returned to the Hacettepe University in 1991 to become Associate Professor of Cardiology, and later Professor of Cardiology in 1998.

Prof. Tokgözoğlu has served on the Executive Committee of the European Society of Atherosclerosis as member between 2003 and 2005, as Secretary between 2005-2009, as Vice President of the European Atherosclerosis Society between 2009-2013 and as President since January 2017. She was the President of the 77th European Atherosclerosis Society meeting in Istanbul. She also served as the President of the ‘Atherosclerosis and Vascular Biology Working Group of the European Society of Cardiology’ between 2008 and 2010. She has served for 2 years on board of the European Society of Cardiology Fellowship and Training Committee and for 2 years on the board of the Education Committee. She has also served first as Member-at-Large (Europe) of the Executive Committee of the International Society of Atherosclerosis, then as President of the European Federation of the International Atherosclerosis Society followed by the post of Secretary of the International Society of Atherosclerosis.

Prof. Tokgözoğlu has served on the Board of the Prevention Association of the European Society of Cardiology chairing their Education Committee. She has been a member of the Young Investigator Award Committees of the International Atherosclerosis Society in Stockholm 2000, European Atherosclerosis Society in Prague in 2005 and has served in the Scientific Program Committe of the European Society of Cardiology in 2009, 2010, 2015, 2016, 2017 and 2018.

Prof. Tokgözoğlu has been elected to the ‘Science Academy in Turkey’ in 2014.

Prof. Tokgözoğlu has served as the Secretary of the Lipid Working Group of the Turkish Society of Cardiology between 1994 and 1996, as President of the Lipid Working Group of the Turkish Society of Cardiology between 1998 and 2000. She has been on the Executive Committee of the Turkish Society of Cardiology for 6 years between 2000 and 2006 and as Vice President between 2008 and 2010 and the President of the Turkish Society of Cardiology between 2014-2016. She was the first female President of this society in its history of 52 years. She has chaired the ‘Research Committee of the Turkish Society of Cardiology’ for 4 years. She is the founding member of the Atherosclerosis Research and Education Society in Turkey. Prof Tokgözoğlu is one of the authors of the ‘National Heart Health Policy’ for Turkey. She has been on the Guideline Committee for the Prevention of Coronary Heart Disease in Turkey in 1995 and in 2002 when the Guidelines were revised.She has also been an author on the EAS/ESC dyslipidemia guideines in 2011. She also received the Paul Dudley White International Science Team Award in 2017.

Prof. Tokgözoğlu is currently a Fellow of the American College of Cardiology and European Society of Cardiology. She is also member of many societies of her specialty. She has won the “Prof. Dr. Şeref Zileli “Resident of the Year” Award in 1987; the Sandoz Scientific Award in 1989 and the “Young Investigator Award” of the Turkish Society of Cardiology in 1994 and second runner up in the Pfizer Cardiology Scientific Award in 1999. She also received the Paul Dudley White International Science Team Award in 2017.